Insilico Medicine Secures $110M Series E for AI Drug Discovery
Deal News | Mar 13, 2025 | eight roads ventures
Insilico Medicine, a clinical-stage company specializing in AI-driven drug discovery, announced a successful $110 million Series E financing round led by Value Partners Group. This funding will be used to advance Insilico's AI technology and drug pipeline developments. Insilico's proprietary AI platform, Pharma.AI, has significantly reduced the drug discovery timeline and costs, with the company now owning a diverse portfolio of drug assets, some of which have shown promising clinical results. The company has also established revenue streams through out-licensing deals and partnerships with major industry players. The involvement of notable investors underscores the confidence in Insilico's approach to transforming biopharmaceutical R&D.
Sectors
- Biotechnology
- Artificial Intelligence
- Pharmaceuticals
- Investment Management
Geography
- United States – Insilico Medicine is based in Cambridge, Massachusetts, and plays a significant role in the US biotechnology sector.
- Hong Kong – Value Partners Group, the leading investor in Insilico's Series E funding, is based in Hong Kong.
- Asia – Value Partners Group, a major investor in this deal, operates extensively in Asia.
- Global – The implications of Insilico Medicine's innovations in AI and drug discovery are globally significant, affecting the broader pharmaceutical and biotechnology industries.
Industry
- Biotechnology – Insilico Medicine operates within the biotechnology sector, focusing on AI-driven drug discovery and development.
- Artificial Intelligence – Insilico Medicine utilizes advanced AI models and platforms to streamline and innovate the drug discovery process.
- Pharmaceuticals – The company is involved in the pharmaceutical industry by developing new drug candidates and securing licensing deals.
- Investment Management – Value Partners Group, as a private equity firm, belongs to the investment management sector.
Financials
- $110 million – Series E financing for Insilico Medicine.
- $2.1 billion – Value of pipeline out-licensing agreements secured by Insilico.
- $1.4 billion – Value of drug discovery and development collaborations.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Insilico Medicine | Target Company | Company | A clinical-stage AI-driven drug discovery company. |
| Value Partners Group | Private Equity Investor | Company | A major asset management firm based in Hong Kong responsible for leading the Series E round. |
| Fosun Pharma | Partner | Company | Participant in out-licensing agreements with Insilico. |
| Exelixis | Partner | Company | Participant in out-licensing agreements with Insilico. |
| Menarini | Partner | Company | Participant in out-licensing agreements with Insilico. |
| Sanofi | Collaborator | Company | Involved in drug discovery collaborations with Insilico. |
| Saudi Aramco | Collaborator | Company | Involved in drug discovery collaborations with Insilico. |
| Therasid Bioscience | Collaborator | Company | Involved in drug discovery collaborations with Insilico. |
| Alex Zhavoronkov, PhD | CEO | Person | Founder and CEO of Insilico Medicine. |
| Dr. Chuen Yan Leung | Partner (Healthcare Investments) | Person | Partner at Value Partners Group. |